|
PhD theses
Movies
Publications
 |
Research output Angiogenesis Laboratory Amsterdam
2012
Van Beijnum, J.R., Nowak-Sliwinska, P.,
Van den Boezem, E., Hautvast, P., Buurman, W.A., Griffioen, A.W. Tumor
angiogenesis is enforced by autocrine regulation of high-mobility group
box 1. Oncogene, In press, 2012.
2011
Paulis,
Y.W.J., Dinnes, D., Soetekouw, P.M.M.B., Nelson, P.J., Burdach, S.,
Loewe, R.P., Tjan-Heijnen, V.C.G., Von Luettichau, I., Griffioen, A.W.
Imatinib reduces the vasculogenic potential of plastic tumor cells.
Current Angiogenesis, In press, 2011.
Siemerink, M.J., Klaassen, I., Vogels,
I.M.C., Griffioen, A.W., Van Noorden, C.J.F., Schlingemann, R.O. CD34
marks angiogenic tip cells in human vascular endothelial cell cultures.
Angiogenesis, In press, 2011.
Gotink, K.J.,
Broxterman, H.J., Labots, M., De Haas, R.R., Dekker, H., Honeywell,
R.J., Beerepoot, L.V., Musters, R.J., Jansen. G., Griffioen, A.W., Pili,
R., Assaraf, Y.G., Peters, G.J., Verheul, H.M.W.
Lysosomal sequestration of sunitinib: a novel mechanism of drug
resistance. Clin. Cancer Res. 17:7337-46, 2011.
Nowak-Sliwinska, P., Weiss A., Van
Beijnum, J.R., Wong T.J., Ballini, J.P., Lovisa, B., Van den Bergh, H.,
Griffioen, A.W. Angiostatic kinase inhibitors to sustain photodynamic
angio-occlusion. J.Cell.Mol.Med.
In press, 2011.
Nilsson, R. J., Balaj, L.,
Hulleman, E., van Rijn, S., Pegtel, D. M., Walraven, M., Widmark, A.,
Gerritsen, W. R., Verheul, H. M., Vandertop, W. P., Noske, D. P., Skog,
J., and Wurdinger, T. Blood platelets contain tumor-derived RNA
biomarkers. Blood, 118: 3680-3683, 2011.
Schneiders, F. L., Scheper, R. J.,
von Blomberg, B. M., Woltman, A. M., Janssen, H. L., van den Eertwegh,
A. J., Verheul, H. M., de Gruijl, T. D., and van der Vliet, H. J.
Clinical experience with alpha-galactosylceramide (KRN7000) in patients
with advanced cancer and chronic hepatitis B/C infection. Clin Immunol,
140: 130-141, 2011.
Van der Veldt, A. A., Vroling, L.,
de Haas, R. R., Koolwijk, P., van den Eertwegh, A. J., Haanen, J. B.,
van Hinsbergh, V. W., Broxterman, H. J., and Boven, E. Sunitinib-induced
changes in circulating endothelial cell-related proteins in patients
with metastatic renal cell cancer. Int J Cancer, 2011.
Shapira, A., Livney, Y. D.,
Broxterman, H. J., and Assaraf, Y. G. Nanomedicine for targeted cancer
therapy: towards the overcoming of drug resistance. Drug Resist Updat,
14: 150-163, 2011.
Laeremans H, Hackeng TM, van Zandvoort MA, Thijssen VL,
Janssen BJ, Ottenheijm HC, Smits JF, Blankesteijn WM. Blocking of Frizzled signaling with a homologous peptide
fragment of Wnt3a/Wnt5a reduces infarct expansion and prevents the
development of heart failure after myocardial infarction. Circulation,
124:1626-35, 2011.
Gianella,
A, Jarzyna PA, Mani V, Ramachandran S, Calcagno C, Tang J, Thijssen VL,
Griffioen, AW, Storm G, Fayad ZA, Mulder WJ, A multifunctional
nanoemulsion platform for imaging guided therapy evaluated in
experimental cancer. ACS Nano, 5:4422-33, 2011.
Nowak-Sliwinska, P, Van Beijnum, JR, Casini, A, Nazarov, A, Wagnières,
G, Van den Bergh, H, Dyson, PJ, Griffioen, AW. Organometallic
ruthenium(II)-arene compounds with anti-angiogenic activity. J.Med.Chem.
54:3895-3902, 2011.
Langenberg MHG, Witteveen
PO, Roodhart J, Lolkema MP, Verheul HMW, Mergui-Roelvink M, Brendel
E, Krätzschmar J, Loembé B, Nol-Boekel A, Christensen O, Schellens JHM,
Voest EE. Phase I evaluation of telatinib, a VEGF receptor tyrosine
kinase inhibitor, in combination with bevacizumab in subjects with
advanced solid tumors. Ann Oncol. 22:2508-15, 2011.
Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg
R, Voest EE, Verheul HM. Antiangiogenic tyrosine kinase inhibition
related gastrointestinal perforations: a case report and literature
review. Angiogenesis
14:135-41,
2011.
Stancic M., van Horssen J., Thijssen V.L., Gabius H-J.,
Bsibsi M., van der Valk P., Hoekstra D., Baron W. Increased expression
of distinct galectins in multiple sclerosis lesions. Neuropath Appl
Neuro. 37:654-71, 2011.
Salomonsson E.,
Thijssen V.L., Griffioen A.W., Nillson U.J., Leffler H.
The anti-angiogenic peptide
anginex greatly enhances galectin-1 binding affinity for glycoproteins.
J Biol Chem. 286:13801-4, 2011
Bijnsdorp I.V., Capriotti F., Losekoot N., Kruyt F.A.E.,
Thijssen V.L., Liekens S., Balzarini J., Griffioen A.W., Fukushima M.,
Peters G.J.
Thymidine phosphorylase in cancer
cells stimulates human endothelial cell migration and invasion by the
secretion of angiogenic factors. Br. J. Cancer. 104:1185-92, 2011
Pardali,
E., Van der Schaft, D.W.J., Wiercinska, E., Gorter, A., Hogendoorn,
P.C.W., Griffioen, A.W., Ten Dijke, P. Critical role of endoglin in
tumor cell plasticity of Ewing Sarcoma and melanoma. Oncogene,
30:334-45,
2011.
Dings, R.P.M., Vang, K.B., Castermans,
K.,
Popescu, F., Zhang, Y., Oude Egbrink, M.G.A., Mescher,
M.F., Farrar, M.A., Griffioen, A.W., Mayo, K.H.
Enhancement of T-cell mediated
anti-tumor response: angiostatic adjuvant to immunotherapy against
cancer. Clin. Cancer Res. 17:3134-45, 2011
Sabrkhany, S.A., Griffioen, A.W., Oude
Egbrink, M.G. The role of blood platelets in tumor angiogenesis. BBA -
Rev. on Canc. 1815:189- 196,
2011.
2010
Nowak-Sliwinska, P., Van Beijnum, J.R., Van Berkel, M.,
Van den Bergh, H., Griffioen, A.W. Vascular regrowth following
photodynamic therapy in the chicken embryo chorioallantoid membrane.
Angiogenesis, 13:281-92. 2010.
Biere, S.S.,
van Weyenberg, S.J., Verheul, H.M., Mulder, C.J., Cuesta, M.A., van der
Peet, D.L. Non-metastasizedoesophageal cancer. Ned. Tijdschr. Geneeskd.
154:A820, 2010.
Snoeren, N.,
Voest, E.E., Bergman, A.M., Dalesio, O., Verheul, H.M., Tollenaar, R.A.,
van der Sijp, J.R., Schouten, S.B., Rinkes, I.H., van Hillegersberg, R.
A randomized two arms phase III study in patients post radical resection
of liver metastases of colorectal cancer to investigate bevacizumab in
combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as
adjuvant treatment. BMC Cancer. 10:545, 2010
Schneiders
F.L., van den Berg, H.P., Peters, G.J., Verheul, H.M., van der Vliet,
H.J. Severe toxicity of capecitabine following uncomplicated treatment
with 5-fluorouracil/leucovorin. Med. Oncol. In press. 2010.
Piersma, S.R., Labots, M., Verheul, H.M., Jiménez, C.R.
Strategies for kinome profiling in cancer and potential clinical
applications: chemical proteomics and array-based methods. Anal Bioanal
Chem. 397:3163-71,
2010.
Mulder, W.J.M., Griffioen, A.W.
Imaging of angiogenesis. Angiogenesis. 13:71-4, 2010.
Thijssen, V.L., Barkan, B., Shoji, H., Aries, I.M.,
Mathieu, V., Deltour, L., Hackeng, T.M., Kiss, R., Kloog, Y., Poirier,
Y., Griffioen, A.W. Tumor cells secrete galectin-1 to enhance
endothelial cell activity. Cancer Res. 70:6216-24, 2010.
Dingemans, A.M.C., Van den Boogaart, V., Vosse, B.A., Van
Suylen, R-J., Griffioen, A.W., Thijssen, V.L. Integrin expression
profiling identifies integrin alpha5 and beta1 as prognostic factors in
early stage non-small cell lung cancer. Mol Cancer. 9:152, 2010.
Mulder, W.J.,
Strijkers, G.J.,
Nicolay, K.,
Griffioen, A.W. Quantum dots for multimodal
molecular imaging of angiogenesis.
Angiogenesis, 13:131-4, 2010.
Vroling, L.,
Lind, J.S., de Haas, R.R., Verheul, H.M., van Hinsbergh, V.W.,
Broxterman, H.J., Smit E.F. CD133(+)
circulating haematopoietic progenitor cells predict for response to
sorafenib plus erlotinib in non-small cell lung cancer patients. Br
J Cancer.
102:268-75.2010
Van Wijk, X.M.,
Oosterhof, A., Van den Broek, S.A., Griffioen, A.W.,
Ten Dam, G.B., Rutjes, F.P., Van Delft, F.L.,
Van Kuppevelt, T.H.
A 4-deoxy analogue of N-acetyl-D-glucosamine inhibits
heparan sulphate expression and growth factor binding in vitro. Exp Cell Res.
316:2504-12, 2010.
Strijkers, G.J.,
Kluza, E., Van Tilborg, G.A.F., Van der Schaft, D.W., Griffioen, A.W.,
Mulder, W.J., Nicolay, K.
Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor
angiogenesis.
Angiogenesis.13(2):161-73,
2010
.
Casal, C., Torres-Callado, AX., Plaza-Calonge Mdel, C.,
Martino-Echarri, E., Ramón Y Cajal, S., Rojo, F., Griffioen, AW.,
Rodriguez-Manzaneque, JC. ADAMTS1 contributes tot the acquisition of an
endothelial-like phenotype in plastic tumor cells. Cancer Res.
1;70(11):4676-86, 2010.
Nowak-Sliwinska, P., Wagnières,
G., Van den Bergh, H., Griffioen, A.W.
Angiostasis-induced vascular normalization can improve photodynamic therapy.
Cell Mol Life Sci.
67(9):1559-60, 2010.
Hammers, H.J., Verheul, H.M., Salumbides, B., Sharma, R.,
Rudek, M., Jaspers, J., Shah, P., Ellis, L., Shen, L., Paesante, S.,
Dykema, K., Furge, K., Teh, B.T., Netto, G., Pili, R. Reversible
epithelial to mesenchymal transition and acquired resistance to
sunitinib in patients with renal cell carcinoma: evidence from a
xenograft study. Mol Cancer Ther. 2010. 9(6):1525-35.
Giovannetti, E., Funel, N., Peters, G.J., Del Chiaro, M.,
Erozenci, L.A., Vasile, E., Leon, L.G., Pollina, L.E., Groen, A.,
Falcone, A., Danesi, R., Campani, D., Verheul, H.M., Boggi, U.
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and
pharmacologic aspects underlying its role in the modulation of
gemcitabine activity. Cancer Res. 70:4528-38, 2010.
Honeywell, R., Yarzadah, K., Giovannetti, E., Losekoot,
N., Smit, E.F., Walraven, M., Lind, J.S., Tibaldi, C., Verheul, H.M.,
Peters, G.J. Simple and selective method for the determination of
various tyrosine kinase inhibitors used in the clinical setting by
liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt
Technol Biomed Life Sci. 2010. 878(15-16):1059-68.
Martilla-Ichihara, F., Castermans,
K., Auvinen, K., Oude Egbrink, M.G.A., Jalkanen, S., Griffioen, A.W.,
Salmi, M. Small molecule inhibitors of vascular adhesion protein-1
reduce the accumulation of myeloid cells into tumors and attenuate tumor
growth in mice. J. Immunol. 184:3164-73, 2010.
Langenberg, M.H., Witteveen, P.O., Roodhart, J.M., Verheul, H.M.,
Mergui-Roelvink, M., van der Sar, J., Brendel, E., Laferriere, N.,
Schellens, J.H., Voest, E.E.
Phase I
evaluation of telatinib, a vascular endothelial growth factor receptor
tyrosine kinase inhibitor, in combination with irinotecan and
capecitabine in patients with advanced solid tumors.
Clin Cancer Res.
16:2187-97, 2010.
Walenkamp,
A.M., Bestebroer, J., Boer, I.G., Kruizinga, R., Verheul, H.M., van
Strijp, J.A., de Haas, C.J. Staphylococcal SSL5 binding to human
leukemia cells inhibits cell adhesion to endothelial cells and
platelets. Cell Oncol.
32:1-10, 2010.
Paulis, Y., Soetekouw, P., Verheul, H.M.,
Tjan-Heijnen, V., Griffioen, A.W.
Signalling pathways in vasculogenic mimicry.
BBA Reviews on Cancer,
1806:18-28,
2010.
Gotink K.J.,
Verheul, H.M. Anti-angiogenic tyrosine kinase inhibitors:what is their
mechanism of action? Angiogenesis, 13:1-14, 2010
Heusschen, R.,
van Gink, M., Griffioen, A.W., Thijssen, V.L.
microRNAs in the
tumor endothelium: novel controls on the angioregulatory switchboard.
BBA Reviews on Cancer,
1805:87-96
2010.
Albrethsen, J., Knol, J. C.,
Piersma, S., Pham, T. V., de Wit, M., Mongera, S., Carvalho, B.,
Verheul, H. M., Fijneman, R. J., Meijer, G. A., and Jimenez, C. R.
Sub-nuclear proteomics in colorectal cancer:Identification of proteins
enriched in the nuclear matrix fraction and regulation in adenoma to
carcinoma progression. Mol Cell Proteomics
9:988-1005, 2010.
Banerji, U., Camidge, D. R.,
Verheul, H. M., Agarwal, R., Sarker, D., Kaye, S. B., Desar, I. M.,
Timmer-Bonte, J. N., Eckhardt, S. G., Lewis, K. D., Brown, K. H.,
Cantarini, M. V., Morris, C., George, S. M., Smith, P. D., and van
Herpen, C. M. The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate)
Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I
Open-Label Multicenter Trial in Patients with Advanced Cancer. Clin
Cancer Res, 16: 1613-1623.
Vroling, L., Lind, J. S., de Haas,
R. R., Verheul, H. M., van Hinsbergh, V. W., Broxterman, H. J., and
Smit, E. F. CD133+ circulating haematopoietic progenitor cells predict
for response to sorafenib plus erlotinib in non-small cell lung cancer
patients. Br J Cancer, 102: 268-275.
Kluza. E, van der Schaft, DW,
Hautvast, PA, Mulder, WJ, Mayo, KH, Griffioen, AW, Strijkers, GJ,
Nicolay, K. Synergistic Targeting of alpha(v)beta(3) Integrin and
Galectin-1 with Heteromultivalent Paramagnetic Liposomes for Combined MR
Imaging and Treatment of Angiogenesis. Nano Letters
10:52-8, 2010.
Chen, W., Jarzyna, P.A., Van Tilborg, G.A.F., Nguyen, V.A., Cormode, D.P.,
Klink, A., Griffioen, A.W., Randolph, G.J., Fisher, E.A., Mulder, W.J.M.,
Fayad, Z.A. RGD-peptide funcionalized and reconstituted high density
lipoprotein nanoparticles as a versatile and multimodal tumor targeting
molecular imaging probe. FASEB J.
24:1689-99. 2010.
van Rooij, E, Fielitz, J, Sutherland, L.B., Thijssen,
V.L., Crijns, H.J., Dimaio, M.J., Shelton, J, De Windt, L.J., Hill,
J.A., Olson, E.N.
Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a
Gender-Specific Pathway of Cardioprotection Mediated by the Estrogen
Receptor. Circ. Res.,
8:106:155-65,
2010.
2009
Overkleeft EN,
Goldschmeding R, van Reekum F, Voest EE, Verheul HM. Nephrotic syndrome
caused by the angiogenesis inhibitor sorafenib. Ann Oncol.
21:184-5,
2009.
Verheul HM,
van Erp K, Homs MY, Yoon GS, van Der Groep P, Rogers C, Hansel DE, Netto
GJ, Pili R. The Relationship of Vascular Endothelial Growth Factor and
Coagulation Factor (Fibrin and Fibrinogen) Expression in Clear Cell
Renal Cell Carcinoma. Urology
75:608-14,
2009.
Adema AD,
Bijnsdorp IV, Sandvold ML, Verheul HM, Peters GJ. Innovations and
opportunities to improve conventional (deoxy)nucleoside and
fluoropyrimidine analogs in cancer. Curr Med Chem. 2009;16(35):4632-43.
van der Vliet
HJ, van der Peet DL, Verheul HM. Case 19-2009: Carcinoma of the
gastroesophageal junction. N Engl J Med. 361:1315,
2009.
Heideman DA,
Thunnissen FB, Doeleman M, Kramer D, Verheul HM, Smit EF, Postmus PE,
Meijer CJ, Meijer GA, Snijders PJ. A panel of high resolution melting
(HRM) technology-based assays with direct sequencing possibility for
effective mutation screening of EGFR and K-ras genes. Cell Oncol.
2009;31(5):329-33.
Broxterman HJ,
Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance
in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat.
12:114-26,
2009.
Adema, A. D., Laan, A. C., Myhren,
F., Fichtner, I., Verheul, H. M., Sandvold, M. L., and Peters, G. J.
Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and
of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin
and docetaxel. Int J Oncol, 36: 285-294, 2009.
Piersma, S. R., Broxterman, H. J.,
Kapci, M., de Haas, R. R., Hoekman, K., Verheul, H. M., and Jimenez, C.
R. Proteomics of the TRAP-induced platelet releasate. J Proteomics,
72: 91-109, 2009.
Verheul, H. M., van Erp, K., Homs,
M. Y., Yoon, G. S., van Der Groep, P., Rogers, C., Hansel, D. E., Netto,
G. J., and Pili, R. The Relationship of Vascular Endothelial Growth
Factor and Coagulation Factor (Fibrin and Fibrinogen) Expression in
Clear Cell Renal Cell Carcinoma. Urology,
75:608-14,
2009.
Witjes CD,
Verhoef C, Verheul HM, Eskens FA. Systemic treatment in hepatocellular
carcinoma; 'A small step for man...'. Neth J Med. 67:86-90, 2009.
Vroling L, van
der Veldt AA, de Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, van
Cruijsen H, Verheul HM, van den Eertwegh AJ, Hoekman K, Boven E, van
Hinsbergh VW, Broxterman HJ. Increased numbers of small circulating
endothelial cells in renal cell cancer patients treated with sunitinib.
Angiogenesis 12:69-79,
2009.
van der Veldt
AA, Boven E, Vroling L, Broxterman HJ, van den Eertwegh AJ, Haanen JG.
Sunitinib-induced hemoglobin changes are related to the dosing schedule.
J Clin Oncol. 27:1339-40,
2009.
Piersma SR,
Broxterman HJ, Kapci M, de Haas RR, Hoekman K, Verheul HM, Jiménez CR.
Proteomics of the TRAP-induced platelet releasate. J Proteomics 72:91-109,
2009
Yarzyna, P.A.,
Skajaa, T., Cormode, D.P., Samber, D., Dickson, S.,
Griffioen, A.W., Fayad, Z.A., Mulder, W.J.
Iron oxide core
oil-in-water emulsions as a multifunctional nanoparticle platform for
tumor targeting and imaging.
Biomaterials,
30:6947-54,
2009.
Tabruyn,, S.P., Memet, S.,
Ave, P., Verhaeghe, C., Struman, I., Martial, J.A., Griffioen, A.W.
NF-kB activation in endothelial
cells is critical for the activity of angiostatic agents, Mol. Cancer
Ther. 8:2645-54, 2009.
Griffioen,
A.W., Vyth-Dreese, F.
Angiostasis as a way to improve immunotherapy. Thromb. Haemost.,
101:1025-31. 2009.
Van Beijnum, J.R., Petersen, K.
Griffioen, A.W.
Tumor endothelium is characterized by a matrix remodeling signature.
Font. Biosci.,
1:216-225,
2009.
Griffioen, AW.
Lymphangiogenesis factors target for therapy?
Blood,
113:4135-6,
2009.
Mulder, W.J.M., Castermans, K., Van Beijnum, J.R., Oude Egbrink, M.G.A.,
Chin, P.T.K., Storm, G., Strijkers, G.J., Griffioen, A.W., Nicolay, K.
Multimodality molecular imaging of tumor angiogenesis using quantum
dots. Angiogenesis, 12:17-24,
2009.
Baldewijns,
M.M., Roskams, T., Ballet, V., Van den Eynden G.G., Van Laere, S.J., Van
der Auwera, I., Lerut, E., De Bruïne, A.P., Thijssen, V.L., Vermeulen, P.B., Van Poppel, H.
Low frequency of lymph node metastasis in clear cell
renal cell carcinoma is related to low lymphangiogenic activity,
BJU International., 103:1626-31, 2009.
Thijssen, V.L. One less
concern.
Nature,
457:628-628,
2009.
Eude-Le Parco,
I., Gendronneau, G., N'Guyen, T., Delacour, D., Thijssen, V.L.,
Edelmann, W., Peuchmaur, M., Poirier, F.
Genetic assessment of the importance of galectin-3 in cancer initiation,
progression and dissemination in mice.
Glycobiology, 19:68-75,
2009.
2008
Van
Tilborg, G.A.F., Mulder, W.J.M., Van der Schaft, D.W.J.,
Reutelingsperger, C.P.M., Griffioen, A.W., Strijkers, G.J., Nicolay, K.
Improved molecular MR imaging of tumor angiogenesis by avidin-induced
clearance of non-bound liposomes. Neoplasia,
10:1459-69,
2008.
Koole, R., Van Schooneveld, M., Hilhorst, J., Mulder, W., Cormode,
D., Strijkers, G., Castermans, K., De Mello Donega, C., Vanmaekelbergh,
D., Griffioen, A.W., Nicolay, K., Fayad, Z., Meijerink,
A. Paramagnetic lipid-coated silica nanoparticles with a fluorescent
quantum dot core: a new contrast agent platform for multimodality
imaging,
Bioconj. Chem., 19:2471-9, 2008.
Castermans,
K., Tabruyn, S.P., Zeng, R., Eppolito, C., Leonard, W.J., Shrikant, P.A.,
Griffioen,
A.W.
Angiostatic activity of the anti-tumor cytokine interleukin-21.
Blood, 112:4940-7,
2008.
Griffioen,
A.W. Anti-angiogenesis; making the tumor vulnerable for the immune
system.
Cancer Immunol. Immunother.
2008;57(10):1553-8.
Van Beijnum, J.R.,
Rousch, M., Castermans, K., Van der Linden, E.,
Griffioen, A.W.
Isolation of endothelial cells from fresh tissues. Nature Protocols,
3:1085-91, 2008.
Griffioen
AW: Angiogenesis, in Cancer Research Encyclopedia,
Schwab M (ed):
Heidelberg, Springer Verlag, 2008.
Hillen,
F., Kaijzel, E.L., Castermans, K., Oude Egbrink, M.G.A., Löwik, C.W.G.M., Griffioen, A.W. A transgenic Tie2-GFP athymic mouse model; a tool
for vascular biology in xenograft tumors, Biochem. Biophys. Res. Comm.
368:364-367, 2008.
Griffioen,
A.W. New entry in angiostatic cancer therapy. Blood
111:1755-1756, 2008.
Van Beijnum,
J.R.,
Buurman, W.A.,
Griffioen, A.W. Convergence and amplification of TLR
and RAGE signalling pathways via HMGB1. Angiogenesis
11:91-99,
2008.
Tabruyn, S.P., Griffioen, A.W. NFkB: friend or foe in angiostatic
therapy. Angiogenesis
11:101-106,
2008.
Thijssen, V.L..,
Hulsmans S,
and Griffioen, A. W. The galectin profile of the endothelium; altered expression and
localization in activated and tumor endothelial cells.
Am J Pathol,
172:545-553, 2008.
Van Beijnum, J. R., Van der Linden, E., and Griffioen, A. W. Angiogenic
profiling and comparison of immortalized endothelial cells for
functional genomics. Exp Cell Res,
314:264-272, 2008.
Hillen, F. and Griffioen, A. W. Tumor vasculature; sprouting
angiogenesis and beyond. Cancer Met. Rev.,
26:489-502,
2008.
2007
Castermans, K,
Griffioen, A. W.
Tumor blood vessels, a
difficult hurdle for infiltrating leukocytes.
Biochim. Biophys. Acta reviews
on
Cancer,
1767:160-174, 2007.
Van der Schaft, D.W., Pauwels, and Griffioen, A.W.
Absence of lymph angiogenesis in
breast cancer. Cancer Lett., 256:283-284, 2007.
Thijssen, V. L., Van Beijnum, J. R.,
Mayo, K.H.,
and Griffioen, A. W. Identification of novel drug targets for
angiostatic cancer therapy; it takes two to tango. Curr. Pharm.
Design, 13:3576-3583,
2007.
Thijssen, V. L., Poirier, F., Baum, L. G., and Griffioen, A. W.
Galectins in the tumor endothelium; opportunities for combined cancer
therapy. Blood,
110:2819-2827, 2007.
Hillen, F., Baeten, C. I., Van de Winkel, A., Creytens,
D., Van der Schaft, D. W., Winnepenninckx, V., and Griffioen, A. W. Leukocyte infiltration and tumor cell
plasticity are parameters of aggressiveness in primary cutaneuous
melanoma. Cancer Immunol. Immunother. 57:97-106, 2007
Mulder, W. J., Griffioen, A. W.,
Strijkers, G. J., Cormode, D. P., Nicolay, K., and Fayad, Z. A.
Magnietic and fluorescent nanoparticles for multimodality imaging.
Nanomedicine, 2:307-324, 2007.
Baldewijns, M. M., Thijssen, V. L., Van den Eynden, G. G., Van Laere, S.
J., Bluekens, A. M., Roskams, T., Van Poppel, H., De Bruine, A. P.,
Griffioen, A. W., and Vermeulen, A. H. High-grade clear cell renal cell
carcinoma has a higher angiogenic activity than low grade renal cell
carcinoma based on histomorphological quantitation and qRT-PCR mRNA
expression profile. Brit J Cancer.
96:1888-1895,
2007.
Tabruyn, S. P.,
Sabatel, C., Verhaeghe, C., Malvaux, L., Castermans, K., Nguyen, N.,
Cornet, A., Griffioen, A. W., Martial, J. A., and Struman, I. 16K human
prolactin overcome endothelial cell anergy and promote leukocyte
infiltration in tumors. Mol. Endocrinol. 21:1422-1429, 2007.
Verhaeghe, C.,
Remouchamps, C., Hennuy, B., Vanderplasschen, A., Chariot, A., Tabruyn,
S. P., Oury, C., and Bours, V. Role of IKK and ERK pathways in intrinsic
inflammation of cystic fibrosis airways. Biochem. Pharmacol.,
73:1982-1994, 2007.
Tabruyn, S. P. and Griffioen, A. W. A new role for NF-kB in angiogenesis
inhibition.
Cell Death Differ., 14:1393-1397, 2007.
Griffioen, A.W. Therapeutic
approaches of angiogenesis inhibition; are we tackling the problem at
the right level? Trends Cardiovas. Med.
17:171-176, 2007.
Dings, R. P.,
Loren, M., Heun, H., McNiel, E., Griffioen, A. W., Mayo, K. H., and
Griffin, R. J. Scheduling of radiation with angiogenesis inhibitors
Anginex and Avastin improves therapeutic outcome via vessel
normalization. Clin Cancer Res. 13:3395-1402, 2007.
Verhaeghe, C., Tabruyn, S. P.,
Oury, C.,
Bours, V., and Griffioen, A. W. An
intrinsic pro-angiogenic status of airway epithelial cells in cystic
fibrosis. Biochem Biophys Res Commun,
356:745-749,
2007.
Van der Schaft, D.W., Pauwels, P., Hulsmans, S., Zimmermann, M.,
Van de Poll-Franse, L.V., and Griffioen, A.W. Lymphatic
vessel density and expression of VEGF-C and -D are not related to tumor
progression and survival in ductal breast cancer. Cancer Lett.,
254:128-136, 2007.
Brandwijk, R. J., Griffioen, A. W.,
and Thijssen, V. L. Targeted gene delivery strategies for angiostatic
cancer treatment. Trends Mol Med. 13:200-209,
2007.
Brandwijk, R. J., Mulder, W. J., Nicolay, K., Mayo, K. H.,
Thijssen, V. L., and Griffioen, A. W.
Anginex conjugated liposomes for targeting of angiogenic
endothelial cells. Bioconjug Chem.
18:785-790, 2007.
Hellebrekers, D.M.E.I.,
Melotte, V., Viré, E., Fuks, F.,
Herman, J.G., Molema, G., Van Criekinge,
W.,
Griffioen, A.W.,
Van Engeland, M.
Identification of
epigenetically silenced genes in tumor endothelial cells. Cancer Res.
67:4138-4148, 2007.
Tabruyn, S.P.,
and Griffioen, A. W.
Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun,
355:1-5, 2007.
Mulder,
W.J.M., Van
der Schaft,
D.W.J.,
Hautvast,
P.A.I.,
Strijkers,
G.J.,
Storm,
G.,
Mayo,
K.H.,
Griffioen, A. W., and Nicolay, K. Early in vivo
assessment of angiostatic therapy efficacy by molecular MRI. FASEB J.,
21:378-383, 2007.
Hellebrekers, D.M.E.I., Griffioen, A.W., Van Engeland, M. Dual targeting
of epigenetic therapy in cancer.
Biochim Biophys Acta
1775:76-91, 2007.
Hillen, F., Melotte, V., Van Beijnum, J.R., Griffioen, A.W., Endothelial cell biology. In: Angiogenesis assays: a critical
appraisal of current techniques. Eds: Carolyn Staton, Claire Lewis, Roy
Bicknell. John Wiley & Sons Ltd, 2007.
2006
Thijssen, V. L., Postel, R., Brandwijk, R. J., Dings, R. P., Nesmelova,
I., Satijn, S. A., Verhofstad, N., Nakabeppu, Y., Baum, L. G., Bakkers, J., Mayo, K. H., Poirier, F., and Griffioen, A. W. Galectin-1 is
essential in angiogenesis and is a target for anti-angiogenesis therapy.
Proc.Natl.Acad.Sci.USA, 103:15975-15980, 2006
Derksen,
P.W., Liu, X., Saradin, F., Evers, B., Van Beijnum, J.R., Griffioen, A.W., Van
der Gulden, H., Zevenhoven, J., Peterse, H., Cardiff, R.,
Vink, J., Krimpenfort, P., Berns, A., and Jonkers, J.
Somatic inactivation of E-cadherin and
p53 in mice leads to metastatic lobular mammary carcinoma through
induction of anoikis resistance and angiogenesis. Cancer Cell,
10:437-449, 2006
Hellebrekers, D. M., Castermans, K., Vire, E., Dings,
R. P., Hoebers, N. T., Mayo, K. H., Oude Egbrink, M. G., Molema, G.,
Fuks, F., van Engeland, M., and Griffioen, A. W. Epigenetic regulation
of tumor endothelial cell anergy; silencing of ICAM-1 by histone
modifications. Cancer Res., 66:10770-10777, 2006.
Griffioen, A. W.
Angiogenesis:
fundamental and clinical perspectives. Angiogenesis,
9:155-170, 2006.
Brandwijk, R. J., Dings, R. P. M., Van der Linden, E., Mayo, K. H., Thijssen, V. L., and Griffioen, A. W. Anti-angiogenesis and anti-tumor
activity of recombinant anginex. Biochem Biophys Res Commun,
349:1073-1078, 2006.
Dirkx, A.E.M., Oude Egbrink, M.G., Wagstaff, J., Griffioen, A.W.
Monocyte/macrophage infiltration in tumors; modulators of angiogenesis.
J.Leuk.Biol. 80:1183-1196, 2006.
Baeten, C.
I., Castermans, K., Lammering, G., Hillen, F., Wouters, B. G., Hillen, H. F.,
Griffioen, A. W., and Baeten, C. M. Effects of radiotherapy and chemotherapy on
angiogenesis and leukocyte infiltration in rectal cancer. Int.J.Radiation Oncology Biol.Phys.,
66: 1219-1227, 2006.
Dings, R.P., Chen, X., Nesmelova, I., Haseman, J., Hellebrekers, D.M.E.I.,
Maxwell, J., Van Eijk, L.I., Hoye, T.R., Griffioen, A.W., Mayo, K.H.,
Design of non-peptidic helix/sheet topomimetics: applications to
inhibition of angiogenesis and tumor growth in mice. J Natl Cancer Inst,
98:932-936, 2006.
Flati, V., Pastore, L.I., Griffioen, A.W., Satijn, S.,
Toniato, E., D'Alimonte, I., Laglia, E., Marchetti, P., Gulino, A.,
Martinotti, S. Endothelial cell anergy is
mediated by bFGF through the sustained activation of p38-MAPK and NF-kB
inhibition. Int.J.Immunopathol.Pharmacol.
19:761-773,
2006.
Hillen, F., Van de Winkel, A., Baeten, C.I.M., Creytens, D., Vermeulen, T., Griffioen, A.W. Proliferating endothelial cells, but
not microvessel density, is a prognostic parameter in human cutaneous
melanoma. Melanoma Res. 16:453-547, 2006.
Van Beijnum, J.R., Dings, R.P.M., Zwaans, B., Van der Linden, E., Ramaekers, F.C.S., Mayo, K.H.
and Griffioen, A. W. Gene expression of tumor angiogenesis dissected; specific targeting
of colon cancer angiogenic vasculature. Blood, 108:2339-2348, 2006.
Baeten,C.I.M., Castermans, K., Hillen, H.F.P., Griffioen, A.W. Proleferatingendothelial cells and leukocyte infiltration are related prognostic markers incolorectal cancer. Clin. Gastroenterol. Hepatol.
4:1351-7, 2006.
Punyadeera,
C., Thijssen, V. L. J. L., Tchaikovski, S., Gashaw, I., Kamps, R., Dunselman, G. A. J., De
Goeij, A. F. P. M., Winterhager, E., Griffioen, A. W., Groothuis, P. G. Biphasic
angiogenesis response in proliferative phase human endometrium. Mol.Hum.Reprod.,
12:367-375, 2006.
Ahmed,
B., Landuyt, W., Griffioen, A. W., van Oosterom, A., Van den Bogaert, W., Lambin, P. In
vivo antitumor effect of combretastatin A-4 phosphate added to fractionated irradiation.
Anticancer Res. 26:307-310, 2006.
Hellebrekers,
D. M. E. I., Jair, K. W., Eguchi, S., Hoebers, N. T. H., Vire, E., Fraga, M. F., Fuks, F.,
Esteller, M., Baylin, S. B., van Engeland, M., Griffioen, A. W. Epigenetic regulation of
angiogenesis; DNA methyltransferase inhibitors have angiostatic activity. Mol.Cancer Ther.
5:467-475, 2006.
Langereis,
S., De Lussanet, Q. R., Van Genderen, M. H. P., Meijer, E. W., Beets-Tan, R. G. H.,
Griffioen, A. W., Van Engelshoven, J. M. A., Backes, W. H. Evaluation of
Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging.
NMR Biomed. 19:133-41, 2006.
Dirkx,
A. E. M., oude-Egbrink, M. G., Castermans, K., Thijssen, V. L. J. L., Van der Schaft, D. W. J., Dings, R.P.M., Kwee, L., Mayo, K. H., Wagstaff, J., Bouma-Ter Steege, J. C. A.,
Griffioen, A. W. Anti-angiogenesis therapy can overcome endothelial cell anergy and
promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J.
20:621-30, 2006.
Van Beijnum, J. R., Eijgelaar, W. J.,
Griffioen, A. W. Target identification and validation in angiogenesis research; a
shift in focus. From gene to function or from function to gene? Trends Mol. Med.,
12(1):44-52, 2006.
Van Beijnum, J.R., Griffioen, A.W. [Genexpressieanalyse
van tumor angiogenese: van target naar therapie. Kanker 30: 6-9, 2006.
Griffioen, A.W., Thijssen, V.L. Angiogenesis: fundamental
and clinical perspectives. Angiogenese Journaal 1:11-13, 2006.
Mulder,
W. J. M., Strijkers, G. J., Van Tilborg, G. A. F., Griffioen, A. W., Nicolay, K. Lipid
based nanoparticles for contrast enhanced MRI and molecular imaging. NMR Biomed.
19(1):142-64, 2006.
Mulder,
W. J. M., Koole, R., Brandwijk, R. J., Storm, G., Chin, P., Strijkers, G. J., Celso de
Mello Donega, Nicolay, K., Griffioen, A. W. Paramagnetic quantum dots as a bimodal
molecular imaging probe for angiogenesis. Nano Letters. 6:1-6, 2006.
2005
Van der Schaft, D. W. J., Hillen, F.,
Pauwels, P., Kirschmann, D. A., Castermans, K., oude Egbrink, M. G. A., Tran, M. G. B.,
Sciot, R., Hauben, E., Hogendoorn, P. C. W., Delattre, O., Maxwell, P. H., Hendrix, M. J.
C., Griffioen, A. W. Tumor cell plasticity in Ewing sarcoma; an alternative circulatory
system stimulated by hypoxia. Cancer Res., 65:11520-8, 2005.
Mulder, W. J. M., Strijkers, G. J., Habets,
J., Bleeker, E. J. W., Van der Schaft, D. W. J., Storm, G., Koning, G. A., Griffioen, A. W., and Nicolay, K. MR Molecular Imaging and Fluorescence Microscopy for identification of
Activated Tumor Endothelium Using a Bimodal Lipidic Nanoparticle. FASEB J., 19:2008-10,
2005..
Van Beijnum, J. R. and Griffioen, A. W. In
silico analysis of angiogenesis associated gene expression identifies angiogenic stage
related profiles. BBA Cancer, 1755:121-34, 2005.
Brandwijk, R., Nesmelova, I., Dings, R. P.
M., Mayo, K. H., Thijssen, V. L. J. L., and Griffioen, A. W. Cloning of an artificial gene
encoding anginex: from rational in silico designed angiostatic peptide to functional
recombinant protein. Biochem.Biophys.Res.Commun., 333:1261-8, 2005.
De Lussanet, Q. R., Backes, W. H., Griffioen,
A. W., Padhani, A. R., Baeten, C. I. M., Van Baardwijk, A., Lambin, P., Beets, G. L., Van
Engelshoven, J. M. A., and Beets-Tan, R. G. H. Dynamic contrast enhanced magnetic
resonance imaging of radiation therapy induced microcirculation changes in rectal cancer.
Int.J.Rad.Oncol.Biol., 63:1309-15, 2005.
Nap, A. W., Dunselman, G. A. J., Griffioen,
A. W., Mayo, K. H., Evers, J. L. H., and Groothuis, P. G. Angiostatic agents prevent the
development of endometriosis-like lesions in the chicken chorioallantoic membrane.
Fertil.Steril., 83:793-5, 2005.
Dings, R. P. M., Williams, B. W., Song, C.
W., Griffioen, A. W., Mayo, K. H., and Griffin, R. Antiangiogenic peptide anginex
synergizes with radiation therapy to cause tumor growth inhibition and regression via
endothelial cell radiosensitization. Int.J.Cancer, 115:312-9, 2005.
De Lussanet, Q. R., Langereis, S., Beets-Tan,
R. G. H., Van Genderen, M., Griffioen, A. W., Van Engelshoven, J. M. A., and Backes, W. H.
Relationship between dynamic contrast-enhanced MR imaging kinetic parameters and molecular
weight of dendritic contrast agents in tumor angiogenesis. Radiology, 235:65-72, 2005.
Nesmelova, I. V., Sham, Y., Dudek, A. Z., Van
Eijk, L. I., Wu, G., Slungaard, A., Mortari, F., Griffioen, A. W., and Mayo, K. H. PF4 and
IL8 CXC-Chemokine heterodimer formation modulates function at the quarternary level.
J.Biol.Chem., 280(6):4948-58, 2005.
2004
Bouma-Ter
Steege, J. C. A., Baeten, C. I. M., Thijssen, V. L. J. L., Satijn, S. A., Verhoeven, I. C. L., Hillen, H. F. P., Wagstaff, J., and Griffioen, A. W. Angiogenic profile of breast
cancinoma determines leukocyte infiltrate. Clin.Cancer Res., 10:7171-8, 2004.
Thijssen, V. L.
J. L., Brandwijk, R., Dings, R. P. M., and Griffioen, A. W. Angiogenesis gene expression
profiling in xenograft models to study cellular interactions. Exp.Cell Res., 299: 286-293, 2004.
Van der Schaft,
D. W. J., Seftor, E. A., Hess, A. R., Gruman, L. M., Yokoyama, Y., Griffioen, A. W., and
Hendrix, M. J. C. Differential effects of angiogenesis inhibitors on vascular network
formation by endothelial cells versus aggressive melanoma tumor cells. J.Natl.Cancer
Inst., 96: 1473-1477, 2004.
Derks S, Lentjes
MH, Hellebrekers DM, de Bruine AP, Herman JG, van Engeland M Methylation-specific PCR
unraveled. Cell Oncol. 26:291-9, 2004.
Griffioen, A. W.
Development of designed angiogenesis inhibitors and peptide-mimetics. Angiogenesis, 6: 356-358, 2004.
Mulder, W. J.
M., Strijkers, G. J., Griffioen, A. W., Van Bloois, L., Molema, G., Storm, G., Koning, G.
A., and Nicolay, K. A liposomal system for contrast-enhanced MR imaging of molecular
targets. Bioconjugate Chem., 15: 799-806, 2004.
Matzen, K.,
Dirkx, A. E. M., oude Egbrink, M. G. A., Speth, C., Goette, M., Quadt, I., Ascherl, G.,
Griffioen, A. W., and Stuerzl, M. HIV-1 Tat increases adhesion of monocytes and T-cells to
the endothelium in vitro and in vivo: Implications for AIDS associated vasculopathy. Virus
Res., 104, 145-155, 2004.
De Lussanet, Q.
R., Beets-Tan, R. G. H., Backes, W. H., Van der Schaft, D. W. J., Van Engelshoven, J. M.
A., Mayo, K. H., and Griffioen, A. W. Dynamic contrast-enhanced magnetic resonance imaging
at 1.5 T with Gd-DTPA to assess angiostatic effects of anginex in mice. Eur.J.Cancer, 40: 1262-1268, 2004.
Nap, A. W.,
Griffioen, A. W., Dunselman, G. A. J., Bouma-Ter Steege, J. C. A., Thijssen, V. L. J. L.,
Evers, J. L. H., and Groothuis, P. G. Anti-angiogenesis therapy for endometriosis.
J.Clin.Endocr.Metab., 83: 1089-1095, 2004.
Van de Wouw, A. J., Jansen, R. L. H., Griffioen, A. W., and Hillen, H. F. P. Clinical and
immunohistochemical analysis of patients with unknown primary tumor. Anticancer Res., 24: 297-301, 2004.
2003
Van Beijnum, J. and Griffioen, A. W.
Transcriptional profiling of angiogenically activated endothelial cells; gene expression
reflects the angiogenic stage. Appl.Genomics Proteomics, 2: 207-223, 2003.
Dings, R. P. M., Nesmelova, I., Griffioen, A. W., and Mayo, K. H. Discovery and development of antiangiogenic peptides: a structural
link. Angiogenesis, 6: 83-91, 2003.
Van Beijnum, J. R., Fan, T. P., and
Griffioen, A. W. Euroconference Angiogenesis II. Angiogenesis, 6: 159-164, 2003.
Mayo, K.H., Dings, R.P.M., Flader, C.,
Nesmelova, I., Hargittai, B., Van der Schaft, D.W.J., Van Eijk, L., Walek, D., Haseman,
J., Hoye, T.R., Griffioen, A.W. Design of a partial-peptide mimetic of anginex with
antiangiogenic and anticancer activity. J.Biol.Chem., 278:45746-45752, 2003.
Mayo, K. H. and Griffioen, A. W. Designing
beta-pep peptides: a rational approach to discovery of novel pharmaceutical agents and
small molecules. Drugs of the Future, 28:337-346, 2003.
Dings, R. P. M., Arroyo, M., Van Eijk, L. I.,
Griffioen, A. W., and Mayo, K. H. Beta-sheet is the bioactive conformation of the
anti-angiogenic peptide anginex. Biochem. J. 373:281-188, 2003.
Dirkx, A., oude Egbrink,
M. G. A., Kuipers, M., Van de Niet, S. T., Heijnen, V. V. T., Wagstaff, J., and Griffioen,
A. W. Tumor angiogenesis modulates leukocyte-vessel wall interactions in relation to tumor
size. Cancer Res., 63:2322-2329, 2003.
Dings RPM, Van der Schaft
DWJ, Hargittai B, Haseman J, Griffioen AW, and Mayo KH. Anti-tumor activity of the
novel angiogenesis inhibitor anginex. Cancer Letters, 35:1-12, 2003
Ahmed B, Van Eijk L,
Bouma-Ter Steege JCA, Van der Schaft DWJ, Van Esch AM, Lambin P, Landuijt W, and Griffioen
AW, A defined role of angiogenesis inhibition in the overall vascular targeting activity
of combretastatin A-4 phosphate. Int.J.Cancer, 104:87-94, 2003.
Dings RPM, Hargittai B,
Haseman J, Griffioen AW, and Mayo KH, The designed angiostatic peptide anginex
synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin.
Cancer Res., 63:382-5, 2003.
De Lussanet, Q. R.,
Backes, W. H., Griffioen, A. W., Van Engelshoven, J. M. A., and Beets-Tan, R. G. H.
Gd-DTPA versus USPIO for dynamic contrast-enhanced MRI of tumor angiogenesis in human
colon carcinoma in mice. Radiology, 229:429-438: 2003.
2002
Jayson GC, Zweit J, Jackson A, Mulatero C,
Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J,
Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang T, Levitt D, Marreaud
S, Lehmann F.F, Herold M, Zwierzina H. Molecular Imaging and Biological evaluation of
HuMV833 anti-VEGF antibody: Implications for trial design of anti-angiogenic antibodies.
J.Natl.Cancer Inst. 2002, 94:1484.
Van der Schaft DWJ, Dings RPM, De Lussanet
QR, Van Eijk LI, Nap AW, Beets-Tan RGH, Bouma-Ter Steege JCA, Wagstaff J, Mayo KH,
Griffioen AW. The designer anti-angiogenic peptide anginex targets tumor endothelial cells
and inhibits tumor growth in animal models. FASEB J., 16:1991-3, 2002.
Baeten CIM, Wagstaff J, Verhoeven ICL, Hillen HFP and Griffioen AW. Flow cytometric quantification of tumor endothelial cells; an
objective alternative for microvessel density assessment. Br.J.Cancer, 87:344, 2002.
Bouma-Ter Steege JCA, Mayo KH, Griffioen AW.
Angiostatic proteins and peptides. Crit.Rev.Euk.Gene Expr. 11: 41-55, 2002
Van der Schaft DWJ, Wagstaff J, Mayo KH,
Griffioen AW. The antiangiogenic properties
of bactericidal/permeability-increasing protein (BPI).. Ann.Med. 34:19-27, 2002.
2001
Griffioen AW:
Angiogenesis, in Schwab M (ed): Cancer Research Encyclopedia,
Heidelberg, Springer
Verlag, 2001.
Van der Schaft DWJ, Ramakrishnan S, Molema G,
Griffioen AW: Tumor vascular targeting, in G.Molema (ed): Organ specific drug targeting.
Springer 2001, pages 233-254.
Mutuberria R, Arends JW, Griffioen AW,
Hoogenboom HR: Phage display technology for target discovery in drug delivery research, in
G.Molema (ed): Organ specific drug targeting.
Springer 2001, pages
255-271.
Griffioen AW, Van der Schaft DWJ,
Barendsz-Janson AF, Cox A, Struijker Boudier HAJ, Hillen HFP, Mayo KH: Anginex, a designed
peptide that inhibits angiogenesis.
Biochem.J. 354:233, 2001.
Groenewegen, G., Griffioen, A.W. Phenotype analysis of
endothelium from the tumor vasculature. In: Tumor angiogenesis and
microcirculation. pp 181-186. New York, Marcel Decker Inc., 2001.
Mayo KH, Van der Schaft
DWJ, Griffioen AW: Designed beta-sheet peptides that inhibit proliferation and induce
apoptosis in endothelial cells. Angiogenesis, 4:15, 2001
2000
Tromp
SC, oude Egbrink MGA, Dings RPM, Van Velzen S, Slaaf DW, Hillen HFP, Tangelder GJ, Reneman
RS, Griffioen AW: Tumor angiogenesis factors reduce leukocyte adhesion in vivo.
Int.Immunol. 12: 671-676, 2000
Griffioen
AW, Molema G: Angiogenesis: potentials for pharmacologic intervention in the treatment of
cancer, cardiovascular diseases and chronic inflammation. Pharmacol.Rev. 52: 237-268, 2000
Yokoyama
Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S: Synergy between angiostatin and
endostatin: inhibition of ovarian cancer growth. Cancer Res. 60: 2190-2196, 2000
Griffioen
AW: AG3340/prinomastat; an evaluation. Curr.Opin.Oncol.Endo.Metabol.Invest.Drugs 1:
573-582, 2000
Van
der Schaft DWJ, Toebes EAH, Haseman J, Mayo KH, Griffioen AW: Bactericidal permeability
increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular
endothelial cells. Blood 96: 176-181, 2000.
Wild
R, Ramakrishnan S, Sedgewick J, Griffioen AW: Computer assisted digital image analysis for
the quantitative assessment of tumor angiogenesis: inhibition by VEGF-toxin conjugate.
Microvasc.Res. 59: 368-376, 2000.
Hillen,
HFP: Unknown primary tumours. Postgrad. Med. 76: 690-693, 2000.
1999
Griffioen AW, Van der
Schaft DWJ, Cox A, Visentin G, Struijker Boudier HAJ, Hillen HFP, Wagstaff J, Mayo KH:
Anginex/ßpep-25, a designed peptide cytokine that inhibits angiogenesis. Proc.Am.Ass
Cancer Res. 40: 433, 1999
Griffioen AW, Relou IAM,
Gallardo Torres HI, Damen CA, Martinotti S, De Graaf JC, Zwaginga JJ, Groenewegen G: Tumor
angiogenesis impairs leukocyte adhesion and rolling under flow conditions. Angiogenesis 2:
45-50, 1999
Pappas NP, Hillen HFP,
Wagstaff J, Griffioen AW: Tumor angiogenesis regulates the tumor immune response.
Ned.Tijdschr.Geneesk.
143: 1555-1559, 1999
Griffioen AW, Damen CA, Mayo K,
Barendsz-Janson AF, Martinotti S, Blijham GH, Groenewegen G: Angiogenesis inhibitors
overcome tumor induced endothelial cell anergy.
Int.J.Cancer 80:
315-319, 1999.
Saleh AW, Hillen HF, Duits
AJ: Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia
patients during hydroxyurea therapy. Acta Haematol. 102: 31-7, 1999
Luykx-de-Bakker SA,
de-Gruijl TD, Scheper RJ, Wagstaff J, Pinedo HM: Dendritic cells: A novel therapeutic
modality. Ann.Oncol. 10: 21-27, 1999.
1998
Griffioen
AW, Barendsz-Janson AF, Mayo KH, Hillen HFP: Angiogenesis, a target for tumor therapy.
J.Lab.Clin.Med. 132: 363-368, 1998
Barendsz-Janson
AF, Griffioen AW, Muller AD, Van Dam-Mieras MCE, Hillen HFP: In vitro tumor angiogenesis
assays: plasminogen lysine binding site 1 (LBS-1) inhibits in vitro tumor induced
angiogenesis. J.Vasc.Res. 35: 109-114, 1998
Griffioen
AW, Fan TP: Merger of Angiogenesis and Angiogenesis Research. Angiogenesis 2: 201-202,
1998
Relou
IAM, Damen CA, Van der Schaft DWJ, Groenewegen G, Griffioen AW: The effect of culture
conditions on endothelial cell phenotype and responsiveness. Tissue Cell 30: 525-530, 1998
Griffioen
AW, Tromp SC, Hillen HFP: Angiogenesis modulates the tumor immune response.
Int.J.Exp.Pathol. 79: 363-368, 1998
Lichtenbeld
H, Barendsz-Janson AF, Van Essen H, Struijker Boudier HAJ, Griffioen AW, Hillen HFP:
Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo
angiogenesis model. Int.J.Cancer 77: 455-459, 1998
Molema
G, Griffioen AW: Rocking the foundations of solid tumor growth by attacking the tumor's
blood supply. Immunol.Today 19: 392-394, 1998
Hillen
HF, Hak LE, Joosten-Achjanie SR, Arends JW: Microvessel density in unknown primary tumors.
Int.J.Cancer 74: 81-5, 1998.
|
